FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:140-144 July 19, 1984 Number 3 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Aluminum frequently accumulates in patients with end-stage renal failure. We investigated the value of long-term, intermittent infusions of deferoxamine for the removal of aluminium from bone in seven patients undergoing long-term maintenance dialysis. Transient rises in serum aluminum levels occurred initially after treatment. Three patients who were studied by bone biopsy had absent or reduced levels of bone aluminum. Histologic studies of bone before and after therapy showed differences similar to those observed between patients with uremia who had an accumulation of aluminum in bone and those who did not. The diagnostic value of rises in the serum aluminum level after a single infusion of deferoxamine was studied in 12 patients with and 10 patients without aluminum accumulation in bone. All patients with bone aluminum had rises in serum aluminum levels, but rises were also observed in some patients without bone aluminum. Thus, the test cannot be used to diagnose aluminum accumulation in bone. Urinary aluminum levels increased significantly after a single infusion of deferoxamine in three patients with kidney transplants and accumulation of aluminum in bone. These findings indicate that deferoxamine is beneficial for the therapy of aluminum accumulation in the bone of patients with renal failure.

This article has been cited by other articles:

• SALUSKY, I. B., GOODMAN, W. G. (2001). Adynamic Renal Osteodystrophy: Is There a Problem?. J. Am. Soc. Nephrol. 12: 1978-1985 [Full Text]  
• Chazan, J. A., Lew, N. L., Lowrie, E. G. (1991). Increased Serum Aluminum: An Independent Risk Factor for Mortality in Patients Undergoing Long-term Hemodialysis. Arch Intern Med 151: 319-322 [Abstract]  
• Brem, A. S., DiMario, C., Levy, D. L. (1989). Perceived Aluminum-Related Disease in a Dialysis Population: A Report From the End-Stage Renal Disease Network 28. Arch Intern Med 149: 2541-2544 [Abstract]  
• Chazan, J. A., Blonsky, S. L., Abuelo, J. G., Pezzullo, J. C. (1988). Increased Body Aluminum: An Independent Risk Factor in Patients Undergoing Long-term Hemodialysis?. Arch Intern Med 148: 1817-1820 [Abstract]  
• Fraser, C. L., Arieff, A. I. (1988). Nervous System Complications in Uremia. ANN INTERN MED 109: 143-153 [Abstract]  
• MILLINER, D. S., NEBEKER, H. G., OTT, S. M., ANDRESS, D. L., SHERRARD, D. J., ALFREY, A. C., SLATOPOLSKY, E. A., COBURN, J. W. (1984). Use of the Deferoxamine Infusion Test in the Diagnosis of Aluminum-Related Osteodystrophy. ANN INTERN MED 101: 775-780 [Abstract]